← Back to Search

Androgen

Testosterone Treatment for Multiple Sclerosis

Phase 1 & 2
Waitlist Available
Led By Rhonda Voskuhl, M.D.
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 12 months
Awards & highlights
Approved for 10 Other Conditions
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

Since men are less likely to develop multiple sclerosis, the hypothesis was that testosterone might be protective in MS. Men with MS for followed untreated for 6 months, followed by a 12 month treatment period with Androgel.

Eligible Conditions
  • Multiple Sclerosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Whole Brain Atrophy Rate

Awards & Highlights

Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: crossover treatment with AndrogelExperimental Treatment1 Intervention
6 months pretreatment, 12 months treatment intervention with Androgel 10 grams of gel containing 100mg of testosterone
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Testosterone
FDA approved

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,567 Previous Clinical Trials
10,312,178 Total Patients Enrolled
7 Trials studying Multiple Sclerosis
339 Patients Enrolled for Multiple Sclerosis
National Multiple Sclerosis SocietyOTHER
98 Previous Clinical Trials
10,554 Total Patients Enrolled
96 Trials studying Multiple Sclerosis
10,200 Patients Enrolled for Multiple Sclerosis
Rhonda Voskuhl, M.D.Principal InvestigatorUniversity of California, Los Angeles
2 Previous Clinical Trials
222 Total Patients Enrolled
2 Trials studying Multiple Sclerosis
222 Patients Enrolled for Multiple Sclerosis
~0 spots leftby Dec 2025